Pavel Šimara

450 total citations
19 papers, 318 citations indexed

About

Pavel Šimara is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Pavel Šimara has authored 19 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 3 papers in Genetics and 3 papers in Hematology. Recurrent topics in Pavel Šimara's work include Pluripotent Stem Cells Research (6 papers), CRISPR and Genetic Engineering (6 papers) and Virus-based gene therapy research (3 papers). Pavel Šimara is often cited by papers focused on Pluripotent Stem Cells Research (6 papers), CRISPR and Genetic Engineering (6 papers) and Virus-based gene therapy research (3 papers). Pavel Šimara collaborates with scholars based in Czechia, United States and Slovakia. Pavel Šimara's co-authors include Irena Koutná, Stanislav Stejskal, Dan S. Kaufman, Aleš Hampl, Pavel Matula, Petr Vaňhara, Mhairi Copland, Tessa L. Holyoake, Steven Grant and G. Vignir Helgason and has published in prestigious journals such as PLoS ONE, International Journal of Molecular Sciences and Leukemia.

In The Last Decade

Pavel Šimara

18 papers receiving 313 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pavel Šimara Czechia 12 209 54 45 43 41 19 318
Methichit Wattanapanitch Thailand 12 283 1.4× 85 1.6× 26 0.6× 69 1.6× 57 1.4× 35 400
Jennifer Pham United States 9 259 1.2× 59 1.1× 43 1.0× 23 0.5× 33 0.8× 17 345
Karen Dyer Montgomery United States 7 301 1.4× 45 0.8× 91 2.0× 23 0.5× 27 0.7× 8 452
Rebecca H. Horton United Kingdom 4 182 0.9× 46 0.9× 77 1.7× 43 1.0× 18 0.4× 8 295
Gunnhildur Ásta Traustadóttir Iceland 13 281 1.3× 132 2.4× 25 0.6× 34 0.8× 32 0.8× 23 446
June Baik United States 12 336 1.6× 20 0.4× 33 0.7× 59 1.4× 105 2.6× 14 391
Elisa Lenti Italy 6 131 0.6× 60 1.1× 24 0.5× 36 0.8× 36 0.9× 8 258
Samuel Milanovich United States 7 207 1.0× 26 0.5× 26 0.6× 64 1.5× 52 1.3× 12 302
Maëlle Lorvellec United Kingdom 8 309 1.5× 106 2.0× 41 0.9× 21 0.5× 29 0.7× 9 396
Anton Selich Germany 11 178 0.9× 58 1.1× 21 0.5× 107 2.5× 54 1.3× 18 312

Countries citing papers authored by Pavel Šimara

Since Specialization
Citations

This map shows the geographic impact of Pavel Šimara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pavel Šimara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pavel Šimara more than expected).

Fields of papers citing papers by Pavel Šimara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pavel Šimara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pavel Šimara. The network helps show where Pavel Šimara may publish in the future.

Co-authorship network of co-authors of Pavel Šimara

This figure shows the co-authorship network connecting the top 25 collaborators of Pavel Šimara. A scholar is included among the top collaborators of Pavel Šimara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pavel Šimara. Pavel Šimara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Koutná, Irena, et al.. (2021). CAR T-Cell Production Using Nonviral Approaches. Journal of Immunology Research. 2021. 1–9. 43 indexed citations
2.
Šimara, Pavel, et al.. (2020). Endothelial Progenitor Cells Produced From Human Pluripotent Stem Cells by a Synergistic Combination of Cytokines, Small Compounds, and Serum-Free Medium. Frontiers in Cell and Developmental Biology. 8. 309–309. 11 indexed citations
3.
Šimara, Pavel, et al.. (2020). Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications. International Journal of Molecular Sciences. 21(15). 5366–5366. 19 indexed citations
4.
Šimara, Pavel, Pavel Matula, Lenka Zajı́čková, et al.. (2019). The Effect of Uncoated SPIONs on hiPSC-Differentiated Endothelial Cells. International Journal of Molecular Sciences. 20(14). 3536–3536. 4 indexed citations
5.
Šimara, Pavel, et al.. (2017). Reprogramming of Adult Peripheral Blood Cells into Human Induced Pluripotent Stem Cells as a Safe and Accessible Source of Endothelial Cells. Stem Cells and Development. 27(1). 10–22. 12 indexed citations
6.
Šimara, Pavel, et al.. (2017). DNA double-strand breaks in human induced pluripotent stem cell reprogramming and long-term in vitro culturing. Stem Cell Research & Therapy. 8(1). 73–73. 27 indexed citations
8.
Stejskal, Stanislav, et al.. (2016). The role of the endoplasmic reticulum stress in stemness, pluripotency and development. European Journal of Cell Biology. 95(3-5). 115–123. 35 indexed citations
9.
Sorokin, Dmitry V., Lenka Stixová, Soňa Legartová, et al.. (2015). Localized movement and morphology of UBF1-positive nucleolar regions are changed by γ-irradiation in G2 phase of the cell cycle. Nucleus. 6(4). 301–313. 9 indexed citations
10.
Stejskal, Stanislav, et al.. (2015). Cell cycle-dependent changes in H3K56ac in human cells. Cell Cycle. 14(24). 3851–3863. 18 indexed citations
11.
Šimara, Pavel, et al.. (2014). Haematopoietic Developmental Potential of Human Pluripotent Stem Cell Lines. Folia Biologica. 60. S90–S94. 2 indexed citations
12.
Šimara, Pavel, et al.. (2014). Generation of Human Induced Pluripotent Stem Cells Using Genome Integrating or Non-integrating Methods. Folia Biologica. 60. S85–S89. 5 indexed citations
13.
Koutná, Irena, Stanislav Stejskal, Pavel Šimara, et al.. (2014). Intravenous insulin therapy during lung resection does not affect lung function or surfactant proteins. BMC Pulmonary Medicine. 14(1). 155–155.
14.
Vaňhara, Petr, Irena Koutná, Stanislav Stejskal, et al.. (2013). Differential effects of insulin and dexamethasone on pulmonary surfactant-associated genes and proteins in A549 and H441 cells and lung tissue. International Journal of Molecular Medicine. 32(1). 211–218. 24 indexed citations
15.
Šimara, Pavel, et al.. (2013). Pluripotent stem cells and gene therapy. Translational research. 161(4). 284–292. 29 indexed citations
16.
Šimara, Pavel, Stanislav Stejskal, Irena Koutná, et al.. (2013). Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR–ABL kinase inhibition. American Journal of Hematology. 88(5). 385–393. 8 indexed citations
17.
Šimara, Pavel, et al.. (2011). The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia. 25(7). 1159–1167. 37 indexed citations
18.
Koutná, Irena, et al.. (2010). Proliferation and differentiation potential of CD133+ and CD34+ populations from the bone marrow and mobilized peripheral blood. Annals of Hematology. 90(2). 127–137. 16 indexed citations
19.
Šimara, Pavel, et al.. (2009). Combination of mRNA and protein microarray analysis in complex cell profiling. Neoplasma. 56(2). 141–149. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026